AB-1015

AB-1015 is an autologous Integrated Circuit T (ICT) cell therapy from Arsenal Biosciences. An autologous Integrated Circuit T cell therapy tested in platinum-resistant ovarian cancer; the sources reached do not name its targets. Its furthest stage is phase 1, for platinum-resistant high-grade serous ovarian, fallopian tube and primary peritoneal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT05617755 terminated; registry reason: 'Active patients have been rolled over to a separate LTFU study.' Whether it works in people has not been established unless a trial below reports it.